Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

5 Common Misconceptions About Medical Device Consulting

Dec 21, 2025

Understanding Medical Device Consulting

Medical device consulting is a specialized field that assists companies in navigating the complex landscape of medical device development and compliance. Despite its importance, there are several misconceptions about what these consultants do and how they operate. In this post, we will explore five common misconceptions about medical device consulting to provide a clearer understanding of this essential service.

medical consulting

Misconception 1: It's Only for Large Companies

One prevalent myth is that medical device consulting is only beneficial for large corporations with vast resources. In reality, consultants are invaluable to companies of all sizes. Startups and small businesses often lack the in-house expertise to handle regulatory, technical, and market challenges. Consultants provide tailored guidance, helping smaller companies bring products to market efficiently.

By leveraging the expertise of a consultant, smaller businesses can level the playing field, ensuring they meet industry standards and avoid costly delays.

Misconception 2: Consultants Are Too Expensive

Another common belief is that hiring a consultant is prohibitively expensive. While there is a cost involved, consider the potential savings in terms of time, resources, and avoiding regulatory pitfalls. Consulting fees are often outweighed by the benefits of successful product launches and reduced risk of non-compliance.

cost savings

Many consultants offer flexible pricing models, such as hourly rates or project-based fees, making their services accessible to a range of budgets.

Misconception 3: They Only Handle Regulatory Affairs

While regulatory compliance is a crucial part of medical device consulting, it is far from the only service offered. Consultants often provide a wide array of services, including:

  • Market research and analysis
  • Product development and innovation strategies
  • Quality management system implementation
  • Training and support for internal teams

This comprehensive support helps companies at every stage of the product lifecycle, from concept to commercialization.

product development

Misconception 4: All Consultants Are the Same

Not all medical device consultants offer the same expertise or services. Some specialize in specific areas, such as regulatory affairs, while others have a broader focus on product development or market strategy. It's important to select a consultant whose skills align with your specific needs.

Research and interview potential consultants to ensure their experience and approach match your company's goals and challenges.

Misconception 5: Consulting Is a One-Time Engagement

Many believe that consulting is a short-term solution, but in reality, building a long-term relationship with a consultant can be highly beneficial. Ongoing support helps companies stay updated on regulatory changes, adapt to market trends, and continually improve their processes.

Establishing a lasting partnership with a consultant can provide continuous value, driving innovation and ensuring compliance as your company grows.

long term partnership

In conclusion, medical device consulting is a versatile and valuable resource for companies looking to succeed in the competitive healthcare market. By dispelling these misconceptions, businesses can make informed decisions and fully leverage the benefits of expert guidance.